Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
96613 studies found for:    United States
Show Display Options
Rank Status Study
1 Not yet recruiting Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
Condition: Multiple Sclerosis
Interventions: Drug: MD1003 100mg capsule;   Drug: PLACEBO
2 Not yet recruiting A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
Condition: Depressive Disorder, Major
Interventions: Drug: Rapastinel;   Drug: Placebo
3 Recruiting Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
Condition: Acne
Interventions: Drug: IDP-121 Lotion;   Drug: IDP-121 Vehicle Lotion
4 Recruiting Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Conditions: Hyperlipidemia;   NAFLD
Interventions: Drug: VK2809;   Drug: Placebo
5 Active, not recruiting Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Rilotumumab
6 Recruiting A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy
Condition: Metastatic Breast Cancer
Interventions: Drug: Atezolizumab;   Drug: Trastuzumab emtansine;   Other: Placebo
7 Not yet recruiting Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
Condition: Severe Aplastic Anemia
Interventions: Drug: Antithymocyte Globulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: UCB HSCT;   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
8 Recruiting A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
Condition: Asthma
Interventions: Drug: MSTT1041A;   Drug: Placebo
9 Not yet recruiting Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
Conditions: Type 2 Diabetes Mellitus;   Heart Failure
Interventions: Drug: Saxagliptin;   Drug: Sitagliptin;   Drug: Placebo to match saxagliptin;   Drug: Placebo to match sitagliptin
10 Not yet recruiting Safety Study of Viaskin Peanut to Treat Peanut Allergy
Condition: Peanut Allergy
Interventions: Biological: Viaskin Peanut 250 mcg;   Biological: Placebo
11 Recruiting Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Condition: Influenza
Intervention: Biological: Fluzone® Quadrivalent Influenza Vaccine, No Preservative
12 Recruiting Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: semaglutide;   Drug: placebo
13 Recruiting A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Condition: Type 2 Diabetes
Interventions: Drug: Insulin degludec/insulin aspart;   Drug: Insulin glargine;   Drug: Insulin aspart
14 Not yet recruiting P3+ Intervention Phase
Condition: Vaccination
Interventions: Behavioral: Control Site;   Behavioral: Intervention Site;   Behavioral: Patient-level Control Group;   Behavioral: Patient-level Intervention Group
15 Enrolling by invitation Open-Label Treatment Extension Study
Conditions: Opioid Use Disorder;   Opioid-related Disorders
Interventions: Drug: Low dose RBP-6000;   Drug: High dose RBP-6000
16 Recruiting Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Drug: Pimecrolimus Cream, 1%;   Drug: Elidel® (pimecrolimus) Cream;   Drug: Placebo of Pimecrolimus Cream, 1%
17 Recruiting MOMENTUM 3 Continued Access Protocol
Condition: Advanced Refractory Left Ventricular Heart Failure
Intervention: Device: HeartMate 3 LVAS
18 Recruiting FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
Interventions: Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
19 Recruiting Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Condition: Rheumatoid Arthritis
Interventions: Drug: Filgotinib;   Drug: Placebo to match filgotinib;   Drug: Adalimumab;   Drug: Placebo to match adalimumab;   Drug: MTX
20 Enrolling by invitation Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
Conditions: Candidiasis, Vulvovaginal;   Yeast Infection;   Mycoses;   Moniliasis, Vulvovaginal;   Vaginitis, Monilial

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years